Effect of Probiotic Lactobacillus (Lacidofil(R) Cap) for the Prevention of Antibiotic-associated Diarrhea: A Prospective, Randomized, Double-blind, Multicenter Study.
10.3346/jkms.2010.25.12.1784
- Author:
Hyun Joo SONG
1
;
Jin Yong KIM
;
Sung Ae JUNG
;
Seong Eun KIM
;
Hye Sook PARK
;
Yoolwon JEONG
;
Sung Pil HONG
;
Jae Hee CHEON
;
Won Ho KIM
;
Hyo Jong KIM
;
Byong Duk YE
;
Suk Kyun YANG
;
Sang Woo KIM
;
Sung Jae SHIN
;
Hyun Soo KIM
;
Jae Kyu SUNG
;
Eun Young KIM
Author Information
1. Department of Internal Medicine and Preventive Medicine, Ewha Womans University School of Medicine, Seoul, Korea. jassa@ewha.ac.kr
- Publication Type:Original Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Probiotics;
Lactobacillus;
Antibiotic-associated Diarrhea
- MeSH:
Adult;
Aged;
Anti-Bacterial Agents/*adverse effects/therapeutic use;
Diarrhea/chemically induced/*prevention & control;
Double-Blind Method;
Female;
Humans;
*Lactobacillus;
Male;
Middle Aged;
Odds Ratio;
Probiotics/*therapeutic use;
Prospective Studies;
Respiratory Tract Infections/drug therapy;
Risk Factors
- From:Journal of Korean Medical Science
2010;25(12):1784-1791
- CountryRepublic of Korea
- Language:English
-
Abstract:
Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic use. There is growing interest in probiotics for the treatment of AAD and Clostridium difficile infection because of the wide availability of probiotics. The aim of this multicenter, randomized, placebo-controlled, double-blind trial was to assess the efficacy of probiotic Lactobacillus (Lacidofil(R) cap) for the prevention of AAD in adults. From September 2008 to November 2009, a total of 214 patients with respiratory tract infection who had begun receiving antibiotics were randomized to receive Lactobacillus (Lacidofil(R) cap) or placebo for 14 days. Patients recorded bowel frequency and stool consistency daily for 14 days. The primary outcome was the proportion of patients who developed AAD within 14 days of enrollment. AAD developed in 4 (3.9%) of 103 patients in the Lactobacillus group and in 8 (7.2%) of 111 patients in the placebo group (P=0.44). However, the Lactobacillus group showed lower change in bowel frequency and consistency (50/103, 48.5%) than the placebo group (35/111, 31.5%) (P=0.01). Although the Lacidofil(R) cap does not reduce the rate of occurrence of AAD in adult patients with respiratory tract infection who have taken antibiotics, the Lactobacillus group maintains their bowel habits to a greater extent than the placebo group.
